Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms.
Asperger
Autism
Clinical trial
Developmental disorders
Facial expression
Metabolomics
N,N-Dimethylglycine
Neuropeptide
Oxytocin
Plasticity
Journal
Molecular autism
ISSN: 2040-2392
Titre abrégé: Mol Autism
Pays: England
ID NLM: 101534222
Informations de publication
Date de publication:
23 02 2021
23 02 2021
Historique:
received:
21
11
2020
accepted:
12
02
2021
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
10
11
2021
Statut:
epublish
Résumé
Oxytocin is expected as a novel therapeutic agent for autism spectrum disorder (ASD) core symptoms. However, previous results on the efficacy of repeated administrations of oxytocin are controversial. Recently, we reported time-course changes in the efficacy of the neuropeptide underlying the controversial effects of repeated administration; however, the underlying mechanisms remained unknown. The current study explored metabolites representing the molecular mechanisms of oxytocin's efficacy using high-throughput metabolomics analysis on plasma collected before and after 6-week repeated intranasal administration of oxytocin (48 IU/day) or placebo in adult males with ASD (N = 106) who participated in a multi-center, parallel-group, double-blind, placebo-controlled, randomized controlled trial. Among the 35 metabolites measured, a significant increase in N,N-dimethylglycine was detected in the subjects administered oxytocin compared with those given placebo at a medium effect size (false discovery rate (FDR) corrected P = 0.043, d = 0.74, N = 83). Furthermore, subgroup analyses of the participants displaying a prominent time-course change in oxytocin efficacy revealed a significant effect of oxytocin on N,N-dimethylglycine levels with a large effect size (P The metabolites changes caused by oxytocin administration were quantified using peripheral blood and therefore may not directly reflect central nervous system changes. Our findings demonstrate an association of N,N-dimethylglycine upregulation with the time-course change in the efficacy of oxytocin on autistic social deficits. Furthermore, the current findings support the involvement of the N-methyl-D-aspartate receptor and neural plasticity to the time-course change in oxytocin's efficacy. A multi-center, parallel-group, placebo-controlled, double-blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders (the date registered: 30 October 2014; UMIN Clinical Trials Registry: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017703 ) (UMIN000015264).
Sections du résumé
BACKGROUND
Oxytocin is expected as a novel therapeutic agent for autism spectrum disorder (ASD) core symptoms. However, previous results on the efficacy of repeated administrations of oxytocin are controversial. Recently, we reported time-course changes in the efficacy of the neuropeptide underlying the controversial effects of repeated administration; however, the underlying mechanisms remained unknown.
METHODS
The current study explored metabolites representing the molecular mechanisms of oxytocin's efficacy using high-throughput metabolomics analysis on plasma collected before and after 6-week repeated intranasal administration of oxytocin (48 IU/day) or placebo in adult males with ASD (N = 106) who participated in a multi-center, parallel-group, double-blind, placebo-controlled, randomized controlled trial.
RESULTS
Among the 35 metabolites measured, a significant increase in N,N-dimethylglycine was detected in the subjects administered oxytocin compared with those given placebo at a medium effect size (false discovery rate (FDR) corrected P = 0.043, d = 0.74, N = 83). Furthermore, subgroup analyses of the participants displaying a prominent time-course change in oxytocin efficacy revealed a significant effect of oxytocin on N,N-dimethylglycine levels with a large effect size (P
LIMITATIONS
The metabolites changes caused by oxytocin administration were quantified using peripheral blood and therefore may not directly reflect central nervous system changes.
CONCLUSION
Our findings demonstrate an association of N,N-dimethylglycine upregulation with the time-course change in the efficacy of oxytocin on autistic social deficits. Furthermore, the current findings support the involvement of the N-methyl-D-aspartate receptor and neural plasticity to the time-course change in oxytocin's efficacy.
TRIAL REGISTRATION
A multi-center, parallel-group, placebo-controlled, double-blind, confirmatory trial of intranasal oxytocin in participants with autism spectrum disorders (the date registered: 30 October 2014; UMIN Clinical Trials Registry: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017703 ) (UMIN000015264).
Identifiants
pubmed: 33622389
doi: 10.1186/s13229-021-00423-z
pii: 10.1186/s13229-021-00423-z
pmc: PMC7903697
doi:
Substances chimiques
Oxytocin
50-56-6
dimethylglycine
7797M4CPPA
Sarcosine
Z711V88R5F
Banques de données
JPRN
['UMIN000015264']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Références
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4389-94
pubmed: 20160081
Biol Psychiatry. 2019 Feb 15;85(4):345-354
pubmed: 30446206
Curr Opin Neurol. 2019 Aug;32(4):635-640
pubmed: 31045620
Ann Gen Psychiatry. 2020 Jun 5;19:38
pubmed: 32518579
Mol Autism. 2020 Apr 9;11(1):24
pubmed: 32272970
Nature. 2012 Jun 13;486(7402):261-5
pubmed: 22699620
PLoS Genet. 2014 May 29;10(5):e1004402
pubmed: 24875834
Brain. 2019 Jul 1;142(7):2127-2136
pubmed: 31096266
J Reprod Dev. 2016 Apr 22;62(2):209-12
pubmed: 26875568
Psychiatry Clin Neurosci. 2016 Feb;70(2):89-99
pubmed: 26394796
Lancet. 2010 Jun 19;375(9732):2152-60
pubmed: 20494434
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:7-13
pubmed: 27296677
Brain Dev. 2017 Sep;39(8):656-664
pubmed: 28438367
Neuroendocrinology. 1995 Nov;62(5):467-78
pubmed: 8559278
PLoS One. 2018 Jan 2;13(1):e0190442
pubmed: 29293598
Toxicology. 2020 Dec 15;446:152613
pubmed: 33086094
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):20953-8
pubmed: 24297883
Schizophr Res. 2013 Aug;148(1-3):111-6
pubmed: 23726720
J Child Psychol Psychiatry. 2007 May;48(5):473-81
pubmed: 17501728
J Autism Dev Disord. 2010 Jun;40(6):677-88
pubmed: 20020319
Appl Environ Microbiol. 2020 Aug 18;86(17):
pubmed: 32631860
Biol Psychiatry. 2013 Aug 1;74(3):180-8
pubmed: 23079235
J Altern Complement Med. 2011 Mar;17(3):271-4
pubmed: 21417812
J Child Psychol Psychiatry. 2004 Nov;45(8):1420-30
pubmed: 15482502
Mol Autism. 2016 Mar 23;7:19
pubmed: 27011784
J Infect Dis. 1981 Jan;143(1):101-5
pubmed: 6163829
Psychoneuroendocrinology. 2015 Dec;62:36-46
pubmed: 26231445
Psychiatry Clin Neurosci. 2015 May;69(5):259-67
pubmed: 25418865
Aust N Z J Public Health. 2001 Oct;25(5):464-9
pubmed: 11688629
J Am Acad Child Adolesc Psychiatry. 2001 Nov;40(11):1293-9
pubmed: 11699803
Anal Chem. 2002 May 15;74(10):2233-9
pubmed: 12038746
J Pers Soc Psychol. 1986 Dec;51(6):1173-82
pubmed: 3806354
Sci Rep. 2017 Jul 7;7(1):4855
pubmed: 28687801
Brain. 2014 Nov;137(Pt 11):3073-86
pubmed: 25149412
Mol Biosyst. 2008 Feb;4(2):135-47
pubmed: 18213407
Endocr Regul. 2004 Mar;38(1):23-8
pubmed: 15147235
Neuropsychopharmacology. 2015 Sep;40(10):2337-46
pubmed: 25824423
Pharmacol Biochem Behav. 1985 Apr;22(4):641-3
pubmed: 2581277
J Autism Dev Disord. 1989 Jun;19(2):185-212
pubmed: 2745388
J Biomed Sci. 2017 Feb 28;24(1):18
pubmed: 28245819
Mol Psychiatry. 2015 Apr;20(4):447-53
pubmed: 25070538
BMC Bioinformatics. 2006 Dec 13;7:530
pubmed: 17166258
Am J Psychiatry. 2016 Dec 1;173(12):1239-1241
pubmed: 27903098
Mol Psychiatry. 2021 Feb;26(2):710-720
pubmed: 30262887
Mol Biosyst. 2011 Apr;7(4):1217-23
pubmed: 21258713
J Neuroendocrinol. 2018 Jul 12;:e12633
pubmed: 29998612
Transl Psychiatry. 2014 Nov 11;4:e480
pubmed: 25386957
J Child Neurol. 2001 Mar;16(3):169-73
pubmed: 11305684
Mol Psychiatry. 2020 Aug;25(8):1849-1858
pubmed: 29955161
Brain. 2015 Nov;138(Pt 11):3400-12
pubmed: 26336909
Endocrinology. 1992 May;130(5):2602-8
pubmed: 1315251
FEBS J. 2008 Jul;275(14):3514-26
pubmed: 18564180
Phys Sportsmed. 1982 Jan;10(1):107-112
pubmed: 29267114
J Autism Dev Disord. 1994 Oct;24(5):659-85
pubmed: 7814313
Front Psychiatry. 2019 Sep 10;10:647
pubmed: 31551836
J Autism Dev Disord. 1999 Jun;29(3):191-4
pubmed: 10425581
Nat Neurosci. 2003 Apr;6(4):384-90
pubmed: 12598900
Neuropsychopharmacology. 2009 Jan;34(1):173-86
pubmed: 18843269
J Cell Mol Med. 2009 Oct;13(10):4229-38
pubmed: 19267885
J Neurosci. 2012 Oct 10;32(41):14109-17
pubmed: 23055480
Neuropeptides. 2012 Oct;46(5):211-5
pubmed: 22884888
Biol Psychiatry. 2010 Apr 1;67(7):692-4
pubmed: 19897177
JAMA Psychiatry. 2014 Feb;71(2):166-75
pubmed: 24352377
Am J Physiol Regul Integr Comp Physiol. 2015 Mar 1;308(5):R431-8
pubmed: 25540103
Neuroscience. 2004;125(4):947-55
pubmed: 15120854
J Physiol. 2009 Jul 1;587(Pt 13):3207-20
pubmed: 19433577
Biol Psychiatry. 2013 Aug 1;74(3):164-71
pubmed: 23510581
Trends Cogn Sci. 2020 Jan;24(1):8-12
pubmed: 31735541
Nat Neurosci. 2014 Mar;17(3):391-9
pubmed: 24464043